The Goldman Sachs Group Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Abbott Laboratories (NYSE:ABT) had its price target cut by equities researchers at The Goldman Sachs Group from $152.00 to $140.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The brokerage presently has a “buy” rating on the healthcare product maker’s stock. The Goldman Sachs Group’s target price suggests a potential upside of 28.81% from the stock’s current price.

Several other analysts have also recently issued reports on ABT. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $147.00 price target on shares of Abbott Laboratories in a report on Thursday, October 16th. Raymond James Financial boosted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Piper Sandler decreased their target price on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday. BTIG Research reduced their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Oppenheimer dropped their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $143.37.

Abbott Laboratories Stock Up 0.1%

Shares of Abbott Laboratories stock traded up $0.08 during trading hours on Friday, hitting $108.69. 2,307,181 shares of the company’s stock traded hands, compared to its average volume of 8,972,974. Abbott Laboratories has a twelve month low of $105.78 and a twelve month high of $141.23. The company has a market cap of $189.00 billion, a PE ratio of 13.65, a PEG ratio of 2.00 and a beta of 0.72. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The stock has a 50 day simple moving average of $125.23 and a 200-day simple moving average of $128.54.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the prior year, the business posted $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. IMG Wealth Management Inc. boosted its position in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after buying an additional 167 shares during the period. Harbor Capital Advisors Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth $27,000. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories during the third quarter valued at about $31,000. Finally, Anfield Capital Management LLC lifted its holdings in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the period. Institutional investors own 75.18% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Several sell‑side analysts kept constructive ratings and still see meaningful upside — Piper Sandler cut its price target to $135 but remains “overweight,” and BTIG trimmed its target to $140 while keeping a “buy” call, signaling continued analyst confidence despite the pullback. Benzinga
• Positive Sentiment: Med tech (devices) and Established Pharmaceuticals delivered strong growth (double‑digit devices, mid‑single to high single pharma), which management says helped offset weakness in other segments and supports the company’s multi‑year growth thesis. Blockonomi
• Positive Sentiment: Market commentators view the pullback as a potential buying opportunity for long‑term investors because Abbott remains a cash‑generative Dividend King with capacity for buybacks and continued margin improvement. MarketBeat
• Neutral Sentiment: Adjusted EPS of $1.50 matched consensus, showing underlying earnings resilience even as revenues lagged; GAAP results included items that lowered headline net income. Press Release
• Neutral Sentiment: Company guidance: Q1 2026 adjusted EPS of $1.120–1.180 (below the ~1.20 consensus) and FY 2026 adjusted EPS of $5.55–5.80 (around consensus). Guidance tempered near‑term expectations but keeps mid/longer‑term growth intact. Press Release
• Negative Sentiment: Revenue missed Street estimates (~$11.46–11.5B reported vs. ~$11.8–11.9B expected); the Nutrition business declined sharply (near‑9% year‑over‑year) and Diagnostics weakened (lower COVID testing and volatility), which triggered the market sell‑off. Reuters Blockonomi
• Negative Sentiment: Unusual bearish positioning: intraday put option volume spiked sharply, indicating heavy hedging or speculative bearish bets that can amplify downward price moves. (Reported market activity)
• Negative Sentiment: Regulatory/legal overhang: documents show India regulators are scrutinizing supply of a codeine‑based cough syrup tied to abuse investigations, introducing potential reputational and compliance risk. Reuters

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.